Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B02BD04Orphan Medicine

Idelvion(albutrepenonacog alfa)

Hemophilia B

Marketing Authorisation Holder: CSL Behring GmbH

EMA Authorisation: 11/05/2016

INN: albutrepenonacog alfa

Indication

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Idelvion — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.